Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for ML-007C-MA (M1/M4 Agonist) in Alzheimer's Disease Psychosis. The expected timing is based on the latest available company guidance and may change.
05/14/26:- VISTA enrollment is ongoing. Topline Phase 2 results remain expected in H2 2027. 08/13/26:- VISTA Phase 2 enrollment remains ongoing. Topline results are expected in H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.